Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


29.01.2018

3 Am J Obstet Gynecol
1 BMC Cancer
1 Clin Cancer Res
1 Eur J Obstet Gynecol Reprod Biol
1 Gynecol Oncol
1 Int J Gynaecol Obstet
2 Lancet Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Obstet Gynecol

  1. BOAC BM, Xiong Y, Apte SM, Wenham RM, et al
    Adherence to practice guidelines is associated with reduced referral times for patients with ovarian cancer.
    Am J Obstet Gynecol. 2018 Jan 15. pii: S0002-9378(18)30018.
    PubMed     Text format     Abstract available

  2. BISHOP EA, Java JJ, Moore KN, Spirtos NM, et al
    Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: A NRG/Gynecologic Oncology Group Study.
    Am J Obstet Gynecol. 2017 Oct 13. pii: S0002-9378(17)31189.
    PubMed     Text format     Abstract available

  3. CHEN PH
    The yolky thecoma.
    Am J Obstet Gynecol. 2017;216:318.
    PubMed     Text format    


    BMC Cancer

  4. O'DONNELL T, Christie EL, Ahuja A, Buros J, et al
    Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer.
    BMC Cancer. 2018;18:87.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  5. BELLONE S, Buza N, Choi J, Zammataro L, et al
    Exceptional response to pembrolizumab in a metastatic, chemotherapy/radiation resistant ovarian cancer patient harboring a CD274/PD-L1-genetic rearrangement.
    Clin Cancer Res. 2018 Jan 19. pii: 1078-0432.CCR-17-1805.
    PubMed     Text format     Abstract available


    Eur J Obstet Gynecol Reprod Biol

  6. RUAN L, Xie Y, Liu F, Chen X, et al
    Serum miR-1181 and miR-4314 associated with ovarian cancer: MiRNA microarray data analysis for a pilot study.
    Eur J Obstet Gynecol Reprod Biol. 2018;222:31-38.
    PubMed     Text format     Abstract available


    Gynecol Oncol

  7. GRAY HJ, Bell-McGuinn K, Fleming GF, Cristea M, et al
    Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
    Gynecol Oncol. 2018 Jan 15. pii: S0090-8258(17)31620.
    PubMed     Text format     Abstract available


    Int J Gynaecol Obstet

  8. SHENG X, Zhong Y, Lu C, Peng J, et al
    Clinical study of hereditary ovarian cancer syndrome in Shandong province, East China.
    Int J Gynaecol Obstet. 2018 Jan 23. doi: 10.1002/ijgo.12447.
    PubMed     Text format     Abstract available


    Lancet Oncol

  9. LEE JM, Nair J, Zimmer A, Lipkowitz S, et al
    Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
    Lancet Oncol. 2018 Jan 17. pii: S1470-2045(18)30009.
    PubMed     Text format     Abstract available

  10. SCAMBIA G, Ferrandina G
    A turning point in the fight against ovarian cancer?
    Lancet Oncol. 2018 Jan 17. pii: S1470-2045(18)30005.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: